Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 May;174(5):673-679.
doi: 10.7326/M20-8101. Epub 2021 Feb 9.

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

Amir Qaseem  1 , Jennifer Yost  2 , Itziar Etxeandia-Ikobaltzeta  1 , George M Abraham  3 , Janet A Jokela  4 , Mary Ann Forciea  5 , Matthew C Miller  5 , Linda L Humphrey  6 ; Scientific Medical Policy Committee of the American College of Physicians; Robert M. Centor, Rebecca Andrews, Ray Haeme
Collaborators, Affiliations
Practice Guideline

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

Amir Qaseem et al. Ann Intern Med. 2021 May.

Erratum in

Update in

Abstract

Clinicians must have access to the best available evidence to inform point-of-care decisions about the use of remdesivir in patients with COVID-19. This article provides updated advice from the American College of Physicians for clinicians based on an updated rapid review.

PubMed Disclaimer

Conflict of interest statement

Disclosures: All financial and intellectual disclosures of interest were declared and potential conflicts were discussed and managed. Dr. Obley participated in discussion of the practice points but was recused from authorship and voting due to a moderate-level conflict of interest (author of supporting systematic review). Drs. Kansagara and Marcucci participated in the discussion but were recused from authorship and voting due to moderate-level conflicts of interest (authors of recent relevant systematic reviews). A record of disclosures of interest and management of conflicts is kept for each SMPC meeting and conference call and can be viewed at www.acponline.org/about-acp/who-we-are/leadership/boards-committees-councils/scientific-medical-policy-committee/disclosure-of-interests-and-conflict-of-interest-management-summary-for-scientific-medical-policy. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-8101.

Figures

Figure.
Figure.. Updated evidence description.
The evidence search and assessment were done by the U.S. Department of Veterans Affairs Evidence Synthesis Program in Minneapolis, Minnesota (4). Updated search for evidence, done through 7 December 2020, aimed to identify RCTs evaluating remdesivir for treatment of COVID-19. COVID-19 = coronavirus disease 2019; RCT = randomized controlled trial.
See this image and copyright information in PMC

Update of

Comment in

References

    1. U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. Accessed at www.fda.gov/news-events/press-announcements/fda-approves-first-treatment... on 3 November 2020.
    1. Wilt TJ, Kaka AS, MacDonald R, et al. Rapid Response: COVID-19: Remdesivir for Hospitalized Adults. Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs; 2020. VA ESP Project 09-009.
    1. Wilt TJ , Kaka AS , MacDonald R , et al. Remdesivir for adults with COVID-19. A living systematic review for an American College of Physicians Practice Points. Ann Intern Med. 5 October 2020. [Epub ahead of print].. doi: 10.7326/M20-5752 - DOI - PMC - PubMed
    1. Kaka AS, MacDonald R, Greer N, et al. Major update: remdesivir for adults with COVID-19. A living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. 9 February 2021. [Epub ahead of print]. doi:10.7326/M20-8148 - PMC - PubMed
    1. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results. N Engl J Med. 2 December 2020. [Epub ahead of print]. doi:10.1056/NEJMoa2023184 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources